Slide 1: Simulations Plus, Inc. Corporate Overview
Simulations Plus, Inc. (AMEX: SLP) Corporate Overview July 2007 simulations plus, inc. g
Slide 2: Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995
Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995 With the exception of historical information, the matters discussed in this presentation are forward looking statements that involve a number of and uncertainties. The actual results of the Company could differ signific
Slide 3: Two Companies
Two Companies * Simulations Plus, Inc. (AMEX:sLP) — Founded 1996 out of Words+, Inc. — global business — IPO June 1997 - no further financing to date — Software for pharmaceutical research and development — Consulting studies for pharmaceutical and drug delivery companies — FutureLab simulations for
Slide 4: Professor Stephen Hawking
Professor Stephen Hawking * One of world’s foremost theoretical astrophysicists feo OF TIME) + Paralyzed with Li Sahl iia aur aoe THE BIG Gehrig’s disease (ALS) BANG TO BLACK HOLES + Has used Wordst software since 1985 for ,—~ speaking, writing, Internet STEPHEN access, environmental W. H AWKING con
Slide 5: Simulations Plus, Inc.
Simulations Plus, Inc. Sunulation and modeling software for pharmaceutical research — ADMET Predictor™/ADMET Modeler™ — ClassPharmer™ — DDDPlus™ — GastroPlus™ Consulting services to the pharmaceutical industry simulations plus, inc. g
Slide 6: ADMET Predictor™
ADMET Predictor™ Solubility Permeabi logP pKa Toxicities HIV-1 activity ete. Eee S,. + Predicts numerous properties of molecules from just their structures, including physicochemical properties and several toxicities + Ranked #1 in accuracy in two independent studies for predicting solubility and lo
Slide 7: ADMET Modeler™
ADMET Modeler™ Integrated with ADMET Predictor - provides complete modeling/prediction capability — used to build all models in ADMET Predictor except for a few simple calculations Speed and model quality unsurpassed — contract studies have shown ability to find useful models from user data (includi
Slide 8: ClassPharmer™
ClassPharmer™ Merge of two products acquired in 2005 — new product is dramatically faster, more flexible, and can process much larger chemical libraries Classifies molecules by “common substructures” using proprietary algorithms Helps chemists identify what it is about molecular structures that caus
Slide 9: DDDPlus™
DDDPlus™ Espen Sp aaa Me tee =] Medium compra | + First and only simulation tool of its kind + Sales continue to come in — industry is learning how to use this unique tool + Strategy going forward: — Continue aggressive marketing and sales activities + Educate formulation scientists on how to use si
Slide 10: GastroPlus™
GastroPlus™ The industry's Gold Standard - most advanced and widely used simulation of oral absorption/pharmacokinetics/pharmacodynamics Strategy going forward: — Ongoing effort to push the state-of-the-art in PBPK modeling is producing excellent results — New features added, including the ability t
Slide 11: Consulting Contracts
Consulting Contracts Growing part of business — Sunulation studies * Troubleshooting problem compounds * Virtual bioequivalence trials * Design of new oral dosage formulations — Structure-property modeling Generates leads for software licenses Identifies unmet needs for software improvements Increas
Slide 12: Collaborations
Collaborations Several pharmaceutical companies (unnamed by request) Dr. Gordon Amidon, University of Michigan Dr. Per Arturrson, Uppsala University, Sweden Dr. Leslie Benet, University of California at San Francisco Dr. Roland Bodmeier, Freie University Berlin Dr. Kurt Enslein, Enslein Research, In
Slide 13: Core Capabilities and Strengths
Core Capabilities and Strengths — Growing team of exceptional scientists and engineers * Chemistry, biochemistry, molecular biology * Chemical engineering, biomedical engineering * Computer science * Augmentative communication (Words+ subsidiary) — Recognized world-class expertise in oral drug det p
Slide 14: Some of Our International Pharma Customers
Some of Our International Pharma Customers (© DAINIPPON PHARMACEUTICAL CO...7D. sanofi~synthelabo ichoen SCHERING CP severing Poxgh Phe Aerio) > a | E es EMPelahoratories @..... ‘SUMITOMO CHEMICAL i SHIONOG! & CO, LTE La, iS i Janssen Pharma_ en Wyeth eats — th wovartis 6 afte simulationsplus, inc.
Slide 15: Selected Income Statement Data
Selected Income Statement Data (in millions except per share data) 39 3Q 29 29 19 19 4Q 4Q Ended | Ended [| Ended | Ended [| Ended | Ended [| Ended | Ended si107 | silos ff 207 | 2neos ff uisons | 1icomsf| asios | acios Revenues gen | size Psos% | nae [sia | soa ff axe | nan Cost of Sales oss. | 043
Slide 16: Balance Sheet (May 31, 2007)
Balance Sheet (in millions) As of May 31, 2007 ASSETS LIABILITIES Cash & cash equivalents $ 3038 Accounts payable $0089 Accounts receivable 2864 Accrued expenses om Other current assets 0590 Current portion deferred revenue (0.073 TOTAL CURRENT ASSETS 6.492 Other current liabilities TOTAL CURRENT LI
Slide 17: Balance Sheet (July 13, 2007)
Balance Sheet (in millions) As of July 13, 2007 ASSETS LIABILITIES Cash & cash equivalents $ 3.455 Accounts payable $0139 Accounts receivable 2.604 Accrued expenses, 0.726 Other current assets 0599 Deferred revenue 0.136 TOTAL CURRENT ASSETS 6.658 Other current liabilities TOTAL CURRENT LIAB. 1.001
Slide 18: Guidance
Guidance ¢ We are increasing our revenues estimate for the fiscal year to an increase of at least $2.9 million over last fiscal year ¢ Although we have always managed to exceed our estimates in the past, there is no guarantee that we will meet this estimate! simulationsplus, inc. g
Slide 19: Revenue History
Revenue History T2 mo esthnate Revenue $2.91VIM dver FYD6 7,000,000 6,000,000 5,000,000 4,000,000 3,000,000 2,000,000 1,000,000 02 03 04 05 06 O7 (eM) Fiscal Year gWords+ O Simulations Plus o Consolidated simulationsplus, inc. g
Slide 20: Russell MicroCap Index
Russell MicroCap Index Simulations Plus was added to the Russell MicroCap index on June 22, 2007. simulationsplus, inc. g
Slide 21: Month Stock Performance
12 Month Stock Performance SIMULATION PLUS INC splite:¥ as of 43-dul-2007 2 15 10 5 2 ‘Sepoe Now06 Jano? Maro?” Hap? Jul07- 9500.0 $00.0 2200.0 F 0.0 copyright 2007 Yahoo! Inc. inbtps//#inance yoo con simulationsplus, inc. ao
Slide 22: Strategic Considerations
Strategic Considerations Aggressive marketing and sales activities have paid off, and will continue Cash position continues to improve — we want to use it to acquire, to continue to hire selected staff, and for possible outsourcing of specific activities to augment internal efforts Ongoing hunt, act
Slide 23: Management & Directors
Management & Directors Walter S. Woltosz , M.S., M.A ¢ Momoko A. Beran, B.S., M.B ‘PA qualified, C Ronald Creeley, B.S., Vice President, Marketing & Sales Michael B. Bolger, Ph.D., Chief Scientist Jeffrey A. Dahlen, B.E.E., President, Wordst, Inc. Board of directors: — David Z. D’Argenio, Ph.D., Dir
Slide 24: Investment Highlights
Investment Highlights Emerging, high-growth market Proprietary multi-platform software Recurring revenue business model Fast-growing and profitable Debt-free Excellent cash position World class scientific team Experienced management team and board simulationsplus, inc. a